NCT06231693View on ClinicalTrials.gov

Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil

TerminatedOBSERVATIONAL
Enrollment

2

Participants

Timeline

Start Date

December 4, 2023

Primary Completion Date

March 26, 2024

Study Completion Date

March 26, 2024

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab deruxtecan

Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting

Trial Locations (2)

Unknown

Research Site, Porto Alegre

Research Site, São Paulo

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Hospital Israelita Albert Einstein

OTHER

lead

AstraZeneca

INDUSTRY

NCT06231693 - Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil | Biotech Hunter | Biotech Hunter